Edit

Contact Us


    Human Verification

    Genomic Tests

    Comprehensive Genomic Profiling using Next-Generation Sequencing with Machine/deep Learning

    Next Generation Sequencing DNA & RNA Testing

    Next Generation Sequencing DNA & RNA Testing

    Solid Tumors

    Solid Tumor

    Profile
    434 Genes
    • TAT


      5-7 Days
    • Indications



      All solid tumors:
      Mutations in 434 genes,
      copy number variation and chromosomal structural abnormalities,
      TMB, MSI, HRD

      -
    • Sample Type

      FFPE
    • Sample Requirements


      1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
    • Results Reported

      DNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching

    Solid Tumor Fusion / Expression Profile

    1408 Genes
    • TAT


      7-10 Days
    • Indications

      ALL Solid tumors:
      Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 & other sarcoma genes
      Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
      ERBB2, MDM2
      Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
      Mutations in all 1400 genes
    • Sample Type

      FFPE
    • Sample Requirements


      1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
    • Results Reported

      RNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching

    Solid Tumor

    Profile Plus
    434/1408 Genes
    • TAT


      7-10 Days
    • Indications


      ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
      MET exon 14 skipping and various alternative splicing,
      MET, HER2,
      EGFR amplification,
      PIK3CA, PTEN, AKT1, RAS and HRD

      -
    • Sample Type

      FFPE
    • Sample Requirements


      1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
    • Results Reported

      DNA+RNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching
    PLUS

    Solid Tumor

    Liquid Biopsy
    277 Genes
    • TAT


      5-7 Days
    • Indications





      Monitoring therapy,
      resistance and relapse



      -
    • Sample Type

      Peripheral blood
    • Sample Requirements



      Peripheral blood: 5-10 ml.
      EDTA tube preferred
    • Results Reported

      DNA
    • Monitoring
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching
    Liquid Biopsy

    Hematology

    Hematology

    Profile
    179 Genes
    • TAT


      5-7 Days
    • Indications




      MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases, VEXAS

      -
    • Sample Type

      Bone marrow,
      Peripheral blood,
      Fresh tissue
    • Sample Requirements

      Bone marrow: 2ml.
      Peripheral blood: 5 ml.
      EDTA tube preferred
      FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
    • Results Reported

      DNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching

    Liquid Biopsy

    Hematology Profile
    179 Genes
    • TAT


      5-7 Days
    • Indications





      cfDNA - MDS, CMML, AML, MPN, lymphoma, MRD, VEXAS


      -
    • Sample Type



      Peripheral blood
    • Sample Requirements




      Peripheral blood: 5-10 ml.
      EDTA tube preferred
      -
    • Results Reported

      DNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching

    Hematology

    Profile Plus
    179/1408 Genes
    • TAT


      7-10 Days
    • Indications



      Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, VEXAS

      Includes IgVH
      -
    • Sample Type

      Bone marrow,
      Peripheral blood,
      Fresh tissue
    • Sample Requirements

      Bone marrow: 2ml.
      Peripheral blood: 5 ml.
      EDTA tube preferred
      FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
    • Results Reported

      DNA+RNA
    • Diagnostic
    • Therapeutic
    • Prognostic
    • Heterogeneity
    • Clinical Trial Matching
    PLUS